A whole virus pandemic influenza H1N1 vaccine is highly immunogenic and protective in active immunization and passive protection mouse models.
about
Evaluation of the sublingual route for administration of influenza H5N1 virosomes in combination with the bacterial second messenger c-di-GMPCell culture-based influenza vaccines: A necessary and indispensable investment for the futureThe specialized proresolving mediator 17-HDHA enhances the antibody-mediated immune response against influenza virus: a new class of adjuvant?H5N1 whole-virus vaccine induces neutralizing antibodies in humans which are protective in a mouse passive transfer modelA pandemic influenza H1N1 live vaccine based on modified vaccinia Ankara is highly immunogenic and protects mice in active and passive immunizationsHigher Immunological Protection of Pandemic 2009 H1N1 Influenza Live Virus Infection than Split Vaccine Against the Homologous Virus for Long Term Immunization in Ferret.Hyperimmune intravenous immunoglobulin containing high titers of pandemic H1N1 hemagglutinin and neuraminidase antibodies provides dose-dependent protection against lethal virus challenge in SCID micePhase I/II randomized double-blind study of the safety and immunogenicity of a nonadjuvanted vero cell culture-derived whole-virus H9N2 influenza vaccine in healthy adults.Immunogenicity and protective efficacy of a Vero cell culture-derived whole-virus H7N9 vaccine in mice and guinea pigs.Matrix-M adjuvanted virosomal H5N1 vaccine confers protection against lethal viral challenge in a murine model.Effect of the influenza A (H1N1) live attenuated intranasal vaccine on nitric oxide (FE(NO)) and other volatiles in exhaled breathPreparation of commercial quantities of a hyperimmune human intravenous immunoglobulin preparation against an emerging infectious disease: the example of pandemic H1N1 influenza.Immunogenicity and tolerability after two doses of non-adjuvanted, whole-virion pandemic influenza A (H1N1) vaccine in HIV-infected individuals.Pandemic influenza vaccine: characterization of A/California/07/2009 (H1N1) recombinant hemagglutinin protein and insights into H1N1 antigen stabilityProtective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection.A study of Chitosan and c-di-GMP as mucosal adjuvants for intranasal influenza H5N1 vaccine.Vero cell culture-derived pandemic influenza vaccines: preclinical and clinical development.Immune responses in pigs vaccinated with adjuvanted and non-adjuvanted A(H1N1)pdm/09 influenza vaccines used in human immunization programmes.Human IgG subclasses: in vitro neutralization of and in vivo protection against West Nile virus.Enhancement of the immunogenicity and protective efficacy of a mucosal influenza subunit vaccine by the saponin adjuvant GPI-0100.Characterization of cross protection of Swine-Origin Influenza Virus (S-OIV) H1N1 and reassortant H5N1 influenza vaccine in BALB/c mice given a single-dose vaccination.Advax, a Delta Inulin Microparticle, Potentiates In-built Adjuvant Property of Co-administered Vaccines.Animal models to assess the toxicity, immunogenicity and effectiveness of candidate influenza vaccines.Influenza vaccines: T-cell responses deserve more attention.Single-walled carbon nanotubes modulate pulmonary immune responses and increase pandemic influenza a virus titers in mice.
P2860
Q21090975-BD5D4618-3BFF-46E3-898F-49D97073B94BQ28084739-C29B570F-9E91-4FE0-BC20-AC84E254064FQ28251512-2E9B90EA-4D0A-48B2-873A-D523704506D7Q28741304-FC7CAB02-A82F-4CDC-AD32-17A84888ED95Q28749671-486C3F24-18AC-4CEB-B94A-FE4BD78D1CC2Q30356268-D2392EFC-5AF1-4C70-A1BA-4006093A2651Q30361437-2CFD49F7-7C87-4FB0-8E4E-38291AF43980Q30368247-448DED51-44CA-4CAE-B0D5-85D5DA514B7EQ30372141-AA8D76B6-24D4-4DFE-ABCE-D995860B5CCFQ30403760-F5C0CD91-DCBB-474F-9AAD-BF5A20652383Q30404880-6B3E37EA-C09C-4A77-BF79-0F4C6FFEE27CQ30407946-1F29596F-7222-4E32-B931-F0119EB6DC28Q30417245-12939137-D2F2-4AF6-A9F0-856EF831EC76Q30422979-3CFBD03B-1316-4D5B-9E1B-A9255B76AED6Q30423733-633547A5-A1ED-4CD6-89C1-AED4587D6908Q30423922-ED53B6A6-4653-48CA-B974-7A018F5FF515Q30429058-E754B339-8CEF-4DDC-B069-6FCABF00BA56Q34199805-56F8D133-888F-4C7F-AF1C-BEA92F41131BQ34529911-3FB476E2-71A1-436E-94F1-1E654DD1ABBEQ34533085-D5DE3F44-4281-4A14-8542-C681023F5565Q36738797-0E11EC96-855F-41E8-8DB9-6DCEBEF09159Q37584248-EA4FF29D-AFFC-422D-8125-E736C0BA6750Q37900305-59A05273-E947-4A34-8A0E-3E71E04FC17FQ38045918-D35D01C9-F8AB-467E-A778-EB73EC5F3DD8Q47132665-AD6B3C92-4F48-43FB-844B-9BB981F06EC9
P2860
A whole virus pandemic influenza H1N1 vaccine is highly immunogenic and protective in active immunization and passive protection mouse models.
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
A whole virus pandemic influen ...... ssive protection mouse models.
@ast
A whole virus pandemic influen ...... ssive protection mouse models.
@en
type
label
A whole virus pandemic influen ...... ssive protection mouse models.
@ast
A whole virus pandemic influen ...... ssive protection mouse models.
@en
prefLabel
A whole virus pandemic influen ...... ssive protection mouse models.
@ast
A whole virus pandemic influen ...... ssive protection mouse models.
@en
P2093
P2860
P1433
P1476
A whole virus pandemic influen ...... ssive protection mouse models.
@en
P2093
Alois Sachslehner
Astrid Kerschbaum
Brian A Crowe
Christa Tauer
Falko G Falkner
Hartmut J Ehrlich
Helga Savidis-Dacho
Ines Mayerhofer
Leopold Grillberger
Manfred Reiter
P2860
P356
10.1371/JOURNAL.PONE.0009349
P407
P577
2010-02-23T00:00:00Z